Development of UV-spectrophotometric method and its validation for estimating contents of Prulifloxacin in Simulated Intestinal Fluid
Abstract
This study was performed with an objective of developing and validating an UV-spectroscopic method for estimating contents of prulifloxacin in simulated intestinal fluid (SIF) i.e. phosphate- buffer media with a pH of 6.8 as per ICH guidelines. The λmax for prulifloxacin in phosphate- buffer media pH 6.8 was found to be 272 nanometer. The calibration curve of drug followed linearity in-between 1-9 μg/ml concentration range and correlation co-efficient value was found equal to 0.9995. We tested this proposed method onto the bulk and marketed pharmaceutical formulation (tablets) also in order to find out contents of drug. Using developed method for estimation of prulifloxacin in SIF, drug was found to be in-between 101.91 and 104.02 % in marketed tablets which shows a good agreement with that of the claimed level. Accuracy of developed method was established through recovery experimentation, performed for three spiked percent concentrations- 75%, 100%, and 125%. The % recovery was found to be in between 97.27 and 101.82%. Low values of % RSD supported accuracy as well as the reproducibility of developed method. Precision of developed method was established by good in-limit intraday and interday experimental variations and through repeatability tests. Values of % RSD less than 2 confirmed about precision of developed method. The ruggedness of the developed method was validated by performing drug estimation by two different performers. This proposed spectroscopic method has proved to be a rapid and successful method for routine analysis of prulifloxacin in simulated intestinal fluid.
Keywords:
Quantitative determination, fluoroquinolone, prulifloxacin, UV-spectrophotometric, validation.DOI
https://doi.org/10.25004/IJPSDR.2020.120103References
Martindale, 36th ed. Pharmaceutical Press, London, 2007, pp. 286.
The Merck Index, 14th ed. Merck and co. Inc, White House Station, New Jercy, 2004, pp. 7908.
Yoshida Y, Mitsuhashi S. Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone. Antimicrob Agents Chemother. 1993;37:793–800.
Ozaki M, Matsuda M, Tomii Y, Kimura K, Segawa J, Kitano M, Kise M, Shibata K, Otsuki M, Nishino T. In vivo evaluation of NM441, a new thiazeto-quinoline derivative.Antimicrob Agents Chemother. 1991;35:2496–2499.
Hooper DC, Wolfson JS. Mechanisms of quinolone action and bacterial killing. In: Quinolone antimicrobial agents, 2nd ed. Washington D. C., American society for microbiology. 1993;pp. 53.
Hooper DC. Mode of action of fluoroquinolones, Drugs. 1999;58:6.
Panchumarthy R . Five novel spectrophotometric methods for quantitative determination of Prulifloxacin in pure and pharmaceutical formulations. Asian Journal of Biomedical and Pharmaceutical Sciences. 2015:1-13.
Purnima H, Patil P, Phale M, Sharma A. Development and Validation of a Stability-Indicating Assay (HPLC) Method for quantitative analysis of Prulifloxacin in Bulk Drug. Journal of Innovations in Pharmaceutical and Biological Sciences. 2015;2(3):300-311.
Singh RM, Singh S, Singh UK, Singh GN, Mathur SC, Saini PK, Yadav A, Gupta V, Duggal D. Development and validation of a RP-HPLC method for estimation of prulifloxacin in tablet dosage form. Indian J Pharm Sci. 2011;73(5):577-579.
Klein Sandra. The use of biorelevant dissolution media to forecast in-vivo performance of a drug. AAPS journal. 2010 Sep;12(3): 397-406.
United States Pharmacopeia. USP 24. Rockville MD: USP Convention, Inc.; 2002.
ICH-Guidelines Q2 (R1), Validation of Analytical Procedures: Text and Methodology. 2005.
ICH (Q2, R1). Note for guidance on validation of analytical methods: Definitions and terminology. International conference on harmonization. 1994:9-13.
Published
Abstract Display: 515 
PDF Downloads: 436 
